These studies confirm the targeting ability of the AT1 peptide under MI and HF conditions and demonstrate that AT1-HSA-MRN-NPs can safely be used in vivo as targeted drug delivery systems for congestive heart failure and related conditions. This evidence concerns the gene AGTR1 and myocardial infarction.